Biology Reference
In-Depth Information
Clerici M, Shearer GM. 1994. The Th1/Th2 hypothesis of HIV infection: new insights. Immunol
Today 15: 575±580.
Debatin K-M, et al. 1994. High expression of APO-1 (CD95) on T lymphocytes from HIV-infected
children. Blood 83: 3101±3103.
Dockrell DH, et al. 1998. The expression of Fas ligand by macrophages and its upregulation by
HIV infection. J Clin Invest 101: 2394±2405.
Douek DC, McFarland RD, Keiser PH, et al. 1998. Changes in thymic function with age and
during the treatment of HIV infection. Nature 396: 690±695.
Estaquier JT, Idziorek F, De Bels F, Barre-Sinoussi F, et al. 1994. Programmed cell death and
AIDS: signi®cance of T cell apoptosis in pathogenic and nonpathogenic primate lentiviral in-
fections. Proc Natl Acad Sci USA 91: 9431±9435.
Finkel TH, et al. 1995. Apoptosis occurs predominantly in bystander cells and not in productive
cells of HIV- and SIV-infected lymph nodes. Nat Med 1: 129±134.
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J,
Lori F, Flexner C, et al. 1999. Latent infection of CD4
T-cells provides a mechanism for lifelong
persistence of HIV-1, even in patients on e¨ective combination therapy. Nat Med 5: 512±517.
Fleury S, et al. 1998. Limited CD4
T cell renewal in early HIV-1 infection: e¨ect of highly active
antiviral therapy. Nat Med 4: 794±801.
Fleury S, et al. 2000. Long-term Kinetics of T cell production in HIV-infected subjects treated with
highly active antiretroviral therapy. Proc Natl Acad Sci USA 97: 5393±5398.
Flexner C. 1998. HIV-1 protease inhibitors. N Engl J Med 338: 1281±1292.
Garcia S, Fevrier M, Dadaglio G, Lecoeur H, Riviere Y, Gougeon M-L. 1997. Potential deleterious
e¨ect of anti-viral cytotoxic lymphocytes through the CD95 (Fas/APO-1)-mediated pathway
during chronic HIV infection. Immunol Lett 57: 53±58.
Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. 1993. Elevated level of
CD38
CD8
cells in HIV infection add to the prognostic value of low CD4
T cell level: results
of 6 years follow-up. J Acquir Immune De®c Syndr 6: 904±912.
Gougeon M-L. 1999. How does programmed cell death contribute to AIDS pathogenesis? In:
Cameron RG, Feuer C (eds). Apoptosis and Its Modulation by Drugs. pp 127±150.
Gougeon M-L, Montagnier L. 1993. Apoptosis in AIDS. Science 260: 1269±1270.
Gougeon M-L, Garcia S, Heeney J, Tschopp R, Lecoeur H, Guetard D, Rame V, Dauguet C,
Montagnier L. 1993. Programmed cell death of T lymphocytes in AIDS related HIV and SIV
infections. AIDS Res Hum Retrov 9: 553±563.
Gougeon M-L, Lecoeur H, Dulioust A, Enouf MG, et al. 1996. Programmed cell death in periph-
eral lymphocytes from HIV-infected persons: the increased susceptibility to apoptosis of CD4
and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol
156: 3509±3520.
Gougeon M-L, Lecoeur H, Boudet F, Ledru E, Marzabal S, Boullier S, Roue R, Nagata S, Heeney
J. 1997. Lack of chronic immune activation in HIV-infected chimpanzees correlates with the
resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a Th1 pheno-
type. J Immunol 158: 2964±2976.
Gougeon M-L, Lecoeur H, Sasaki Y. 1999. The CD95 system in HIV infection. Impact of
HAART. Immunol Lett 66: 97±103.
Gougeon ML, Rouzioux C, Liberman I, Burgard M. Viard J-P, Bouchenafa K, Capitant C,
Delfraissy JF, Levy Y, the ANRS 048 group. 2000. IL-2 therapy combined with dual nucleoside
analogs could lead to long term reduction in the pool of HIV-1 infected cells and preservation of
HIV speci®c immune responses. Submitted for publication
Groux H, Torpier G, Mont
Â
D, Mouton Y, Capron A, Ameisen J-C. 1992. Activation-induced
death by apoptosis in lymphocytes from human immunode®ciency virus-infected asymptomatic
individuals. J Exp Med 175: 331±340.
